TACHIPIRINA 500 mg compresse

DRUG3 trials

Sponsors

E Pharma Trento S.p.A., Dompe' Farmaceutici S.p.A., Istituto Di Ricerche Farmacologiche Mario Negri

Conditions

Chronic low back painPrimary Membranous NephropathyUpper respiratory tract infections

Phase 2

A phase 2, multicenter, randomized, double blind, active controlled, parallel group study assessing the analgesic effect and safety of two doses of DFL24412 in patients with chronic low back pain compared to Ketoprofen Lysine Salt (KLS)

CompletedCTIS2024-513940-27-00

Dompe' Farmaceutici S.p.A.Chronic low back pain

Start: 2021-11-19End: 2024-12-30Target: 150Updated: 2024-09-16

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Active, not recruitingCTIS2024-515857-93-00

Istituto Di Ricerche Farmacologiche Mario NegriPrimary Membranous Nephropathy

Start: 2021-12-17Target: 20Updated: 2024-12-20

Phase 3

Randomized, multiCentre, dOuble-blind, double-duMmy, parallel-group clinical study on efficacy and safety of iBuprofen/N-acetylcysteine fixed dose cOmbination vs. its individual components (ibuprofen and N- acetylcysteine monotherapies) in patients with symptomatic uncomplicated upper respiratory tract infections with wet cough COMBO

WithdrawnCTIS2023-505809-17-00

E Pharma Trento S.p.A.Upper respiratory tract infections

Target: 483Updated: 2023-11-09